STRO · Sutro Biopharma, Inc. · Metrics
Market Cap
$254.36M
Shares
16.58M
STRO metrics
53 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$15.34
Market cap
$254.36M
Price action
20 metricsPrice change (1W)
-9.0%
Price change (30D)
-25.1%
Price change (3M)
-48.2%
Price change (6M)
-25.8%
Price change (YTD)
+32.6%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
83.8%
Annualized volatility (3M)
67.9%
Beta
1.1
RSI (14D)
21.2
Price vs SMA 50
-30.2%
Price vs SMA 200
—
Avg volume (3M)
357,669
Relative volume
1.8
Average dollar volume
$8.71M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
16.58M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
5.6×
reciprocal yield 18.0%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-71.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.6×
reciprocal yield 171.7%
EV / revenue historical average (5Y)
2.1×
reciprocal yield 48.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-12
Profitability
9 metricsGross margin
—
Operating margin
-319.6%
Trailing 12 months
Net margin
-395.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$146.05M
Net income (TTM)
−$180.64M
Trailing 12 months
Diluted EPS (TTM)
$-17.33
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-84.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$45.70M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+94.7%
Year over year · more shares
Revenue CAGR (3Y)
+14.8%
Revenue CAGR (5Y)
+19.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-92.9%
Debt / equity
—
Current ratio
3.3
EBITDA (TTM)
−$139.99M
Free cash flow (TTM)
—
Quick ratio
3.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$54.34M
Total assets
$194.46M
Total debt
$4.06M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$145.17M
Capital expenditures (TTM)
$2.23M
R&D (TTM)
$144.74M
SG&A (TTM)
—
Stock compensation (TTM)
$6.78M
R&D / revenue
316.7%
Stock compensation / revenue
14.8%
Ownership (13F)
3 metrics13F filers
98
13F filer change QoQ
+20
Institutional ownership
99.5%
Short interest
3 metricsShort interest
10.9%
Latest settlement · 8.5 days to cover
Days to cover
8.5d
Short-squeeze score
60 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—